10,929 Shares in Gilead Sciences, Inc. $GILD Acquired by N.E.W. Advisory Services LLC

N.E.W. Advisory Services LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 10,929 shares of the biopharmaceutical company’s stock, valued at approximately $1,381,000.

A number of other large investors have also bought and sold shares of GILD. HBK Sorce Advisory LLC bought a new stake in shares of Gilead Sciences in the second quarter valued at $4,011,000. Johnson Wealth Management LLC bought a new position in shares of Gilead Sciences during the 2nd quarter worth $2,413,000. J.Safra Asset Management Corp purchased a new stake in Gilead Sciences in the 2nd quarter worth about $35,000. Flputnam Investment Management Co. purchased a new stake in Gilead Sciences in the 2nd quarter worth about $8,963,000. Finally, Global Retirement Partners LLC bought a new stake in Gilead Sciences in the 2nd quarter valued at about $4,372,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on GILD. Royal Bank Of Canada lifted their target price on shares of Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research note on Wednesday, August 5th. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a report on Wednesday, May 20th. Daiwa Securities Group reduced their price objective on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, May 19th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 target price on shares of Gilead Sciences in a research report on Wednesday, August 5th. Finally, Rothschild & Co Redburn reduced their price target on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Twenty-four analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $158.04.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $138.36 on Monday. The company has a 50 day moving average of $130.11 and a 200 day moving average of $136.44. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The stock has a market cap of $171.56 billion, a P/E ratio of -51.82 and a beta of 0.32. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. During the same period in the prior year, the company posted $2.01 EPS. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post -0.53 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.4%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s payout ratio is presently -122.85%.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the sale, the chief financial officer owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This trade represents a 1.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $123.92, for a total value of $371,760.00. Following the transaction, the insider directly owned 124,234 shares of the company’s stock, valued at $15,395,077.28. The trade was a 2.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,000 shares of company stock worth $6,568,860 in the last ninety days. 0.30% of the stock is currently owned by insiders.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Appeals court ruling protects Gilead’s distribution channels. A U.S. appeals court upheld an injunction preventing alternative funding programs and related businesses from importing Gilead medications overseas. The decision could reduce the size of the alternative funding industry and help protect Gilead’s pricing, sales channels and patient-assistance economics. Court rules companies can’t import Gilead medications from overseas in blow to AFP health programs
• Positive Sentiment: Q2 growth highlighted continued commercial momentum. Gilead’s HIV franchise led year-over-year sales growth, with Biktarvy and PrEP performing particularly well. Quarterly PrEP sales reportedly doubled to more than $1 billion, while Trodelvy, Livdelzi and progress in oncology and liver disease added to the growth outlook. 5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
• Positive Sentiment: AI collaboration strengthens the oncology pipeline. Gilead partnered with Nucleai to use AI-powered tissue analytics in its antibody-drug-conjugate programs. The technology is intended to accelerate biomarker discovery and improve precision-oncology development. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Merck partnership offers longer-term growth potential. Recent clinical and regulatory progress involving Gilead and Merck’s collaboration reinforces the possibility that the partnership could produce meaningful future growth in areas such as oncology and infectious disease. Could Merck and Gilead’s Partnership Create the Next Big Pharma Growth Engine
• Neutral Sentiment: Analysts and investors continue to debate whether Gilead remains attractively valued after its strong multiyear performance. High call-option activity signals bullish positioning but does not guarantee sustained gains.
• Negative Sentiment: An analyst reduced the FY2026 EPS forecast, potentially reflecting concerns about earnings normalization, expenses or pipeline investment. The revision may limit near-term upside despite Gilead’s solid revenue trends. FY2026 EPS Forecast for Gilead Sciences Reduced by Analyst

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.